Compare

Kisspeptin vs MOTS-c

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

Kisspeptin

1292 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 56% · Mixed 28% · Unfavorable overall 16%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Appetite control
75
Energy
132
Mood
49
Focus
174
Sleep quality
122

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

GI discomfort
171
Dizziness
31
Fatigue
14
Nausea
169
Water retention
121

Self-reported dose per injection

Median bucket: 100–200 mcg · Most common: 100–200 mcg

Reports span 10–1000 mcg

10–25
8
25–50
12
50–100
22
100–200
31
200–400
20
400–600
16
600–1000
10

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing16stacking29side effects22kisspeptin25

How repeat users are trending

Among repeat reporters, 66% said they felt similar to their last entry, 36% more positive, and 16% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 19 days · Based on 284 repeat reporters

MOTS-c

103 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 67% · Mixed 18% · Unfavorable overall 15%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Energy
182
Mood
55
Focus
174
Sleep quality
32
Lean mass
37

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Dizziness
98
Fatigue
135
Nausea
139
Water retention
27
Appetite loss
36

Self-reported dose per injection

Median bucket: 0.6–1 mg · Most common: 0.6–1 mg

Reports span 0.1–3 mg

0.1–0.2 mg
2
0.2–0.4 mg
5
0.4–0.6 mg
10
0.6–1 mg
20
1–2 mg
15
2–3 mg
4

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing27stacking10side effects33mots-c11

How repeat users are trending

Among repeat reporters, 62% said they felt similar to their last entry, 41% more positive, and 17% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 21 days · Based on 23 repeat reporters

Sources (11)

Published sources linked on the Kisspeptin and MOTS-c wiki pages.

  1. PubMed

    Kisspeptin signaling in reproductive biology

    Pinilla L, Aguilar E, Dieguez C, et al. Physiol Rev. 2012

    Source
    Wiki study page →
  2. PubMed

    Kisspeptin in the control of reproduction

    Skorupskaite K, George JT, Anderson RA. Fertil Steril. 2018

    Source
    Wiki study page →
  3. ClinicalTrials.gov

    Kisspeptin studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  4. PubMed

    Pubertal development and regulation

    Abreu AP, Kaiser UB. The lancet. Diabetes & endocrinology. 2016

    Source
    Wiki study page →
  5. PubMed

    MOTS-c is an ancient mitochondrial-encoded regulator of metabolic homeostasis

    Lee C, Zeng J, Drew BG, et al. Cell Metab. 2015

    Source
    Wiki study page →
  6. PubMed

    MOTS-c: A mitochondrial-encoded peptide regulating muscle function

    Reynolds JC, Lai RW, Woodhead JST, et al. Nat Commun. 2021

    Source
    Wiki study page →
  7. PubMed

    MOTS-c improves insulin sensitivity in mice and humans

    Kim SJ, Xiao J, Wan J, et al. Aging Cell. 2019

    Source
    Wiki study page →
  8. ClinicalTrials.gov

    MOTS-c metabolic studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  9. PubMed

    MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation

    Zheng Y, Wei Z, Wang T. Frontiers in endocrinology. 2023

    Source
    Wiki study page →
  10. PubMed

    MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism

    Lee C, Kim KH, Cohen P. Free radical biology & medicine. 2016

    Source
    Wiki study page →